Teladoc Health, Inc. (NYSE:TDOC - Get Free Report) shares saw unusually-high trading volume on Wednesday after The Goldman Sachs Group raised their price target on the stock from $14.00 to $16.00. The Goldman Sachs Group currently has a buy rating on the stock. Approximately 14,679,102 shares traded hands during mid-day trading, an increase of 115% from the previous session's volume of 6,820,760 shares.The stock last traded at $13.17 and had previously closed at $13.11.
A number of other analysts have also commented on TDOC. Barclays lifted their price objective on Teladoc Health from $10.00 to $12.00 and gave the stock an "overweight" rating in a research report on Thursday, October 31st. Piper Sandler reiterated an "overweight" rating and issued a $13.00 price objective (up from $11.00) on shares of Teladoc Health in a research report on Wednesday, December 4th. Deutsche Bank Aktiengesellschaft lifted their price objective on Teladoc Health from $10.00 to $12.00 and gave the stock a "hold" rating in a research report on Friday, November 1st. Oppenheimer reduced their target price on Teladoc Health from $14.00 to $12.00 and set an "outperform" rating on the stock in a report on Friday, January 24th. Finally, Bank of America raised their target price on Teladoc Health from $11.50 to $13.50 and gave the stock a "neutral" rating in a report on Wednesday, February 12th. Fourteen investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $12.18.
View Our Latest Research Report on Teladoc Health
Insider Activity at Teladoc Health
In other Teladoc Health news, insider Carlos Nueno sold 2,389 shares of the business's stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $11.93, for a total transaction of $28,500.77. Following the transaction, the insider now owns 2,890 shares of the company's stock, valued at $34,477.70. The trade was a 45.25 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.95% of the stock is owned by insiders.
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the stock. Vise Technologies Inc. increased its holdings in shares of Teladoc Health by 4.9% during the 4th quarter. Vise Technologies Inc. now owns 30,179 shares of the health services provider's stock worth $274,000 after acquiring an additional 1,405 shares during the last quarter. PharVision Advisers LLC bought a new stake in Teladoc Health in the 4th quarter valued at $301,000. Twinbeech Capital LP boosted its stake in Teladoc Health by 63.8% in the 4th quarter. Twinbeech Capital LP now owns 382,735 shares of the health services provider's stock valued at $3,479,000 after purchasing an additional 149,118 shares during the period. Two Sigma Advisers LP boosted its stake in Teladoc Health by 213.0% in the 4th quarter. Two Sigma Advisers LP now owns 2,258,711 shares of the health services provider's stock valued at $20,532,000 after purchasing an additional 1,537,094 shares during the period. Finally, Two Sigma Investments LP bought a new stake in Teladoc Health in the 4th quarter valued at $18,348,000. Institutional investors and hedge funds own 76.82% of the company's stock.
Teladoc Health Price Performance
The company has a 50 day moving average of $10.52 and a 200-day moving average of $9.41. The firm has a market capitalization of $1.98 billion, a P/E ratio of -2.00 and a beta of 1.05. The company has a current ratio of 1.73, a quick ratio of 1.69 and a debt-to-equity ratio of 0.66.
Teladoc Health Company Profile
(
Get Free Report)
Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.
See Also
Before you consider Teladoc Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teladoc Health wasn't on the list.
While Teladoc Health currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
